Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENRICH-AF
NCT03950076Phase 4Completed
- Sponsor
- Population Health Research Institute
- Start
- Sep 2019
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 4, randomised, open-label trial of edoxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Population Health Research Institute. Primary endpoints: Stroke or Systemic Embolism at 3 years and Major hemorrhage at 2 years. Started Sep 2019; status: completed.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03950076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950076.